Vaginal mAB Delivery Systems

阴道 mAB 输送系统

• 批准号: 8515321
• 负责人: Thomas Ray Moench
• 金额: $ 7.85万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8515321
• 关键词: Antibodies; Categories; Cervix Uteri; Data; Development; Devices; Effectiveness; Failure; HIV; Human; Immune system; Infection; Instruction; Methods; Monoclonal Antibodies; System; Tenofovir; Vagina; Vaginal Diaphragm; Vaginal Gel; Vaginal Ring; base; microbicide; novel; prevent; small molecule; vaginal microbicide

The recent successful trial of tenofovir vaginal gel provides important proof of concept indicating that a vaginal microbicide can prevent HIV. However, the limited protection observed (39% overall), argues for the development of additional microbicide agents and methods to deliver them. This IPCP application will develop a monoclonal antibody (Mab) based microbicide, distinct from the small molecule antiretrovirals that dominate the current microbicide pipeline. Mabs show promise in providing safe, potent, and specific, yet broad-spectrum microbicide action. Project 4 will attempt to enhance Mab effectiveness by its focus on the means of Mab delivery. Limitations on microbicide effectiveness can be divided into two categories: first, intrinsic failure of the method to provide protection when used (

最近对替诺福韦阴道凝胶的成功试验提供了重要的概念证明，表明阴道杀菌剂可以预防艾滋病毒。然而，所观察到的保护有限（总体为 39%），因此需要开发额外的杀微生物剂以及提供这些杀微生物剂的方法。该 IPCP 申请将开发一种基于单克隆抗体 (Mab) 的杀菌剂，与目前主导杀菌剂产品线的小分子抗逆转录病毒药物不同。单克隆抗体有望提供安全、有效、特异且广谱的杀菌作用。项目 4 将尝试通过关注 Mab 递送方式来提高 Mab 有效性。杀微生物剂有效性的限制可分为两类：第一，该方法在使用时无法提供保护（